Sildenafil (DB00203): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Developmental History

Executive Summary

Sildenafil is a small molecule drug that functions as a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), an enzyme critical to the regulation of blood flow in specific tissues.[1] It is globally recognized under its original brand name, Viagra, for the treatment of erectile dysfunction (ED), and as Revatio for the management of pulmonary arterial hypertension (PAH).[3] The discovery of sildenafil represents a landmark case of pharmaceutical serendipity; it was initially investigated in the late 1980s and early 1990s as a potential treatment for angina pectoris, a form of cardiovascular disease.[1] When clinical trials revealed its limited efficacy for angina but a pronounced and unexpected effect on penile erections, the drug's developmental trajectory was famously redirected.[6]

The pharmacological basis of sildenafil's action lies in its ability to enhance the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway. By inhibiting PDE5, sildenafil prevents the degradation of cGMP, leading to prolonged smooth muscle relaxation and vasodilation in the corpus cavernosum of the penis and the pulmonary vasculature.[1] This mechanism requires sexual stimulation to initiate the release of NO, meaning the drug facilitates a natural physiological response rather than inducing an artificial one.[1]

Its clinical utility in ED and PAH is well-established through extensive clinical trials. However, its vasodilatory properties also dictate its safety profile. The most critical safety consideration is an absolute contraindication for use with organic nitrate medications, as the combination can lead to severe and potentially fatal hypotension.[3] Other adverse effects, such as headache, flushing, and visual disturbances, are generally mild and mechanistically linked to its vasodilatory action in various tissues.[8]

First approved for medical use in 1998, sildenafil not only provided the first effective oral therapy for ED but also profoundly impacted societal discourse, destigmatizing discussions around sexual health and establishing ED as a treatable medical condition.[1] Its subsequent approval for PAH demonstrated its versatility and solidified its status as a paradigm of both serendipitous discovery and rational, mechanism-based drug repurposing.[5] Now widely available as a generic medication, sildenafil continues to be a cornerstone therapy with millions of prescriptions written annually worldwide.[1]

The Serendipitous Discovery and Development of Sildenafil

The history of sildenafil is one of the most celebrated examples of serendipity in modern drug discovery, a narrative that underscores the roles of scientific curiosity, keen observation, and strategic flexibility in pharmaceutical research and development. Its journey from a failed cardiovascular agent to a cultural and medical phenomenon illustrates how an unexpected clinical finding can redefine a molecule's therapeutic destiny.

Origins in Cardiovascular Research

The origins of the program that ultimately yielded sildenafil date to the mid-1980s at Pfizer's research facility in Sandwich, Kent, UK.[11] The primary scientific objective was the development of a novel treatment for cardiovascular conditions, specifically hypertension and angina pectoris.[5] Angina is characterized by chest pain resulting from insufficient blood flow to the heart muscle. The prevailing hypothesis among Pfizer chemists was that a compound capable of selectively inhibiting the enzyme phosphodiesterase type 5 (PDE5) could induce vasodilation in the coronary arteries, thereby increasing blood flow and alleviating anginal symptoms.[7] In 1989, this research effort led to the synthesis of the compound UK-92,480, which would later be known as sildenafil.[11]

Pivotal Clinical Trials and the Unexpected Finding

Following promising preclinical data, sildenafil entered human clinical trials. A Phase I study in healthy volunteers was initiated in 1991 to assess safety and tolerability.[11] This was followed by a Phase II trial in 1992 involving patients with angina, which was designed to evaluate the drug's efficacy for its intended purpose.[11] The results were underwhelming. Sildenafil produced only modest and clinically insignificant hemodynamic effects on the coronary arteries, and it was largely deemed a failure as an anti-anginal agent.[11] The project was on the verge of termination.[13]

The project's fate, however, was altered by an unexpected and consistently reported side effect. During the trials, particularly a study involving Welsh miners at Morriston Hospital in Swansea, male participants began reporting an unusual effect: an increased frequency of spontaneous penile erections that occurred for several days after dosing.[7] One participant noted having more erections during the night than normal, a sentiment echoed by others in the trial.[13] This observation was diligently recorded and reported by clinical staff, including what one account described as "a very observant nurse" who noted that many male subjects were embarrassed because the drug was working, but in the wrong part of the body.[7]

This was not merely a case of passive luck, but rather a demonstration of the critical importance of observational acuity and rigorous data collection in clinical research. The discovery hinged on a system prepared to recognize and document an unexpected human phenotype that was entirely unrelated to the study's primary endpoints. Without the diligence of the clinical staff and the willingness of researchers to investigate an anomaly in a "failed" drug, this pivotal finding could have been easily dismissed.

The Strategic Pivot

The reports of erections created a dilemma within Pfizer. While the drug had failed for its primary indication, it showed a remarkable and potent effect on a different physiological system. Researchers like David Brown and Dr. Ian Osterloh, who was in charge of the drug's clinical development, championed the need to explore this new potential application.[13] Persuading management to invest further in a compound already labeled a failure was a significant challenge. Resources were planned years in advance, and diverting funds to study impotence, a condition not considered a strategic priority at the time, required considerable internal advocacy.[14] After persistent efforts, management was convinced to fund a new set of trials focused on erectile dysfunction.[13]

Redevelopment for Erectile Dysfunction

The subsequent clinical development program for ED was rapid and innovative. Researchers designed over 21 randomized, placebo-controlled trials involving more than 4,000 men with ED of various etiologies.[13] These studies required novel methodologies to objectively quantify erectile response in a clinical setting. For instance, some trials utilized a RigiScan, a device that measures the frequency, rigidity, and duration of erections.[13] To ensure a standardized stimulus for arousal, some studies even necessitated obtaining a Home Office license to use pornographic films, a unique challenge in the pre-internet era.[13] The results were conclusive, showing that approximately 75% to 80% of men treated with sildenafil experienced a clinically significant improvement in erectile function, compared to only about 25% of those on placebo.[13]

Regulatory Approval and Market Launch

With robust efficacy and safety data in hand, Pfizer filed a patent for the use of sildenafil to treat erectile dysfunction in 1994, which was granted in 1996.[3] The company submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), and in a remarkably short review period of less than six months, Viagra was approved on March 27, 1998, becoming the first oral medication for ED.[4]

The market launch was an unprecedented commercial success. Demand was immediate and overwhelming, with urologists reportedly issuing as many as 10,000 prescriptions per day in the drug's early days.[6] Viagra quickly became a household name and a blockbuster drug for Pfizer, with annual sales peaking at over $2.05 billion in 2012.[6]

The Full Circle: Repurposing for Pulmonary Arterial Hypertension

The story of sildenafil came full circle years later. The original mechanism of action—vasodilation via PDE5 inhibition—that had been explored for angina was rationally revisited for another cardiovascular condition. Scientists recognized that the same mechanism that relaxed smooth muscle in the penis could also relax smooth muscle in the pulmonary vasculature, where PDE5 is also expressed.[1] This led to a new development program, and in June 2005, the FDA approved sildenafil under the brand name Revatio for the treatment of pulmonary arterial hypertension (PAH).[6]

This dual history establishes sildenafil as a quintessential paradigm for drug repurposing. The initial pivot from angina to ED was a classic case of serendipitous repurposing driven by an unexpected clinical observation. The subsequent development for PAH was a model of rational, mechanism-based repurposing, applying a known pharmacological effect to a new disease context. This journey demonstrates how a deep understanding of a drug's fundamental mechanism can unlock multiple therapeutic applications, creating a "pipeline in a pill".[1]

Chemical and Physicochemical Profile

The precise chemical identity and physicochemical properties of sildenafil are fundamental to understanding its biological activity, formulation, and pharmacokinetic behavior. As a synthetic small molecule, its structure was rationally designed to interact with its biological target with high affinity and selectivity.

Chemical Identification

Sildenafil is identified by a standardized set of chemical names and codes to ensure unambiguous communication in scientific and regulatory contexts.

• Generic Name: Sildenafil.[1]
• IUPAC Name: The systematic name assigned by the International Union of Pure and Applied Chemistry is 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine.[1] Minor variations in nomenclature exist across different chemical databases but refer to the same molecular entity.[20]
• Synonyms: During its development, it was known by the research code UK-92,480 or UK-92,480-10.[2]

Molecular Structure and Formula

Sildenafil's therapeutic action is a direct result of its unique molecular architecture.

• Molecular Formula: C22​H30​N6​O4​S.[2]
• Molecular Weight: 474.58 g/mol (often rounded to 474.6 g/mol).[3]
• Structural Description: Chemically, sildenafil is a complex heterocyclic compound. It is classified as a pyrazolo[4,3-d]pyrimidin-7-one derivative.[2] Its core structure is a fused ring system (the pyrazolopyrimidine) which is substituted at three key positions:

1. A methyl group at the 1-position.
2. A propyl group at the 3-position.
3. A 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. This structure incorporates functional groups from several chemical classes, including a pyrazolopyrimidine, a piperazine, and a sulfonamide.2

The molecular architecture of sildenafil is a deliberate and elegant example of rational drug design, engineered to function as a molecular mimic of cGMP, the natural substrate for the PDE5 enzyme.[24] This structural similarity is the key to its mechanism as a competitive inhibitor.[4] The pyrazolo[4,3-d]pyrimidin-7-one core of sildenafil was specifically chosen because it possesses a size, shape, and dipole moment that closely resembles the guanosine base of cGMP.[24] The various substituents were then strategically added to optimize its interaction with the enzyme's active site. For instance, the ethoxyphenyl sulfonyl group was designed to occupy the same region of the active site as the phosphate group of cGMP, while the propyl group extension fills a space normally occupied by the ribose sugar.[24] Furthermore, the addition of the polar 4-methylpiperazine moiety was a critical modification that not only improved the drug's aqueous solubility but was also found to enhance its affinity for the enzyme.[24] This intricate design explains

why sildenafil binds so potently and selectively to PDE5, effectively outcompeting cGMP and producing its therapeutic effect.

Physicochemical Properties

• Physical Form: Sildenafil base is a white to off-white crystalline solid.[20]
• Solubility: It has limited solubility in water, with reported values of 3.5 mg/mL and 0.46 mg/mL under different conditions.[1] It is more soluble in organic solvents such as dimethylformamide (DMF) and dimethyl sulfoxide (DMSO).[20] For clinical use, it is often formulated as the citrate salt (sildenafil citrate) to improve solubility and bioavailability.[2]
• Lipophilicity (LogP): The partition coefficient (LogP) is reported to be between 1.8 and 1.87, indicating moderate lipophilicity, which allows it to cross cell membranes and distribute into tissues.[1]
• Acidity/Basicity (pKa): Sildenafil has both acidic and basic functional groups. The strongest acidic pKa is 11.14 (associated with the pyrimidinone nitrogen), and the strongest basic pKa is 5.99 (associated with the piperazine nitrogen).[1]

Standardized Identifiers

To facilitate its identification in global databases, sildenafil is assigned numerous unique identifiers. A consolidated list is provided in Table 1.

Table 1: Key Chemical and Drug Identifiers for Sildenafil

Identifier Type	Value	Source Snippet(s)
Generic Name	Sildenafil	1
IUPAC Name	1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine	1
Molecular Formula	C22​H30​N6​O4​S	2
Molecular Weight	474.58 g/mol	3
CAS Number (Base)	139755-83-2	2
CAS Number (Citrate)	171599-83-0	2
DrugBank ID	DB00203	1
PubChem CID	135398744	3
ChEMBL ID	CHEMBL192	2
UNII	3M7OB98Y7H	2
SMILES	CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1	2
InChIKey	BNRNXUUZRGQAQC-UHFFFAOYSA-N	20

Pharmacological Profile: Mechanism of Action

The therapeutic effects of sildenafil in both erectile dysfunction and pulmonary arterial hypertension are derived from a single, well-defined pharmacological mechanism: the potent and selective inhibition of cGMP-specific phosphodiesterase type 5 (PDE5).[1] Understanding this mechanism is crucial to appreciating its clinical efficacy, its requirement for sexual stimulation, and its safety profile.

The Nitric Oxide/Cyclic Guanosine Monophosphate (NO/cGMP) Signaling Pathway

Sildenafil does not act in a vacuum; it modulates a fundamental physiological signaling pathway that regulates vascular tone.

• Physiology of Penile Erection: In the natural setting, sexual stimulation triggers the release of the neurotransmitter nitric oxide (NO) from non-adrenergic, non-cholinergic (NANC) nerve terminals and endothelial cells within the corpus cavernosum of the penis.[1] NO diffuses into adjacent smooth muscle cells and activates the enzyme soluble guanylate cyclase.[1] This enzyme catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).[4]
• Role of cGMP: cGMP acts as a critical second messenger. It activates cGMP-dependent protein kinase (PKG), which in turn phosphorylates various downstream targets. This cascade ultimately leads to a decrease in intracellular calcium concentrations and the deactivation of myosin light chain kinase, resulting in the relaxation of the smooth muscle cells lining the cavernosal arteries and sinusoids.[4] This relaxation allows for a dramatic increase in arterial blood inflow, causing the sinusoidal spaces to engorge with blood. This expansion compresses the subtunical venules against the rigid tunica albuginea, trapping the blood and producing a firm erection.[4]
• Termination of Erection: The erectile response is naturally terminated when cGMP is hydrolyzed and inactivated by the PDE5 enzyme, which converts it back to GMP. This restores smooth muscle tone, reduces blood inflow, and allows venous outflow, leading to detumescence.[1]

Sildenafil's Role as a Competitive Inhibitor

Sildenafil intervenes at the final step of this pathway. By acting as a competitive inhibitor of PDE5, sildenafil prevents or minimizes the breakdown of cGMP.[1] This leads to an accumulation of cGMP within the smooth muscle cells, thereby amplifying and prolonging the smooth muscle relaxation initiated by NO.[1]

A critical aspect of this mechanism is that sildenafil's action is dependent on the initial activation of the NO/cGMP pathway. The drug does not cause the production of cGMP; it merely protects the cGMP that is already present. Consequently, if there is no sexual stimulation, there is no release of NO, no production of cGMP, and thus nothing for sildenafil to act upon.[1] This directly explains why sildenafil is not an aphrodisiac and does not cause spontaneous erections; it only enhances the natural erectile response to sexual arousal. This distinction between an "enhancer" and an "initiator" is fundamental to its pharmacology and is crucial for patient education and managing therapeutic expectations.[29]

Potency and Selectivity

The clinical success of sildenafil is attributable not only to its mechanism but also to its high potency and, crucially, its selectivity for the target enzyme.

• Potency: Sildenafil is a highly potent inhibitor of PDE5, with reported half-maximal inhibitory concentrations (IC50​) in the low nanomolar range. Studies have documented IC50​ values of 3.0 nM in isolated human corpus cavernosum, 3.6 nM in isolated rabbit platelets, and 5.22 nM in other assays.[19]
• Selectivity: There are at least 11 families of phosphodiesterase enzymes in the human body, each with distinct tissue distributions and functions. Sildenafil's therapeutic utility and safety profile are highly dependent on its selectivity for PDE5 over other isoenzymes. It is approximately 80 times more selective for PDE5 than for PDE1 (found in the brain and vascular smooth muscle) and over 10,000 times more selective for PDE5 than for PDE3 (critical for cardiac contractility).[20] This high degree of selectivity minimizes off-target effects, particularly the potentially dangerous cardiac effects that would arise from PDE3 inhibition.

However, the selectivity profile is not perfect. Sildenafil is only approximately 10-fold more selective for PDE5 than it is for PDE6, an enzyme found in the photoreceptor cells of the retina that is essential for the phototransduction cascade.[4] This relative lack of selectivity for PDE5 over PDE6 is the direct mechanistic explanation for the drug's characteristic visual side effects. Inhibition of PDE6 interferes with the normal processing of light signals, leading to transient symptoms such as blurred vision, increased light sensitivity, and cyanopsia—a bluish tinge to vision.[4] This provides a clear example of how a drug's selectivity profile can explain both its targeted efficacy and its predictable adverse effects.

Mechanism in Pulmonary Arterial Hypertension (PAH)

The same fundamental mechanism of PDE5 inhibition underlies sildenafil's efficacy in PAH. The PDE5 enzyme is also highly expressed in the smooth muscle cells of the pulmonary vasculature.[1] By inhibiting PDE5 in this tissue, sildenafil leads to an accumulation of cGMP, causing vasodilation of the pulmonary vascular bed.[1] This relaxation reduces pulmonary arterial pressure and pulmonary vascular resistance, which in turn alleviates the workload on the right ventricle of the heart, improving exercise capacity and delaying disease progression in patients with PAH.[4]

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of sildenafil—its absorption, distribution, metabolism, and excretion (ADME)—determines its onset and duration of action, dosing frequency, and potential for drug interactions. These properties are essential for its safe and effective clinical use.

Absorption

• Rate and Extent: Sildenafil is rapidly absorbed following oral administration.[1] In a fasted state, peak plasma concentrations ( Cmax​) are typically achieved within 30 to 120 minutes, with a median time to peak concentration (Tmax​) of 60 minutes.[1] This rapid absorption aligns with the clinical recommendation to take the drug approximately one hour prior to sexual activity.[4] The onset of physiological effect can be observed within 20 to 30 minutes.[3]
• Bioavailability: The mean absolute oral bioavailability of sildenafil is approximately 41% (with a range of 25-63%).[1] This value, being less than 100%, indicates that a significant portion of the orally administered dose is eliminated by first-pass metabolism in the liver before it reaches systemic circulation.
• Effect of Food: The rate of absorption is affected by food. When taken with a high-fat meal, the absorption of sildenafil is slowed, resulting in a mean delay in Tmax​ of about 60 minutes and a mean reduction in Cmax​ of approximately 29%.[1] While the rate is slowed, the overall extent of absorption, as measured by the area under the concentration-time curve (AUC), is not significantly affected, decreasing by only about 11%.[1] This pharmacokinetic interaction explains the clinical observation that taking sildenafil with a heavy meal may delay its onset of action.[1]

Distribution

• Volume of Distribution: Sildenafil distributes extensively into the body's tissues. The mean steady-state volume of distribution (Vd​) is 105 L, a value significantly larger than the volume of total body water, confirming its widespread tissue penetration.[1] Preclinical data also indicate that sildenafil can cross the blood-brain barrier.[11]
• Protein Binding: Both sildenafil and its primary active metabolite, N-desmethylsildenafil, are highly bound to plasma proteins, with approximately 96% of the drug being bound.[1] This high degree of protein binding means that only a small fraction of the total drug in the plasma is free (unbound) and pharmacologically active.

Metabolism

• Metabolic Pathway: Sildenafil is extensively metabolized, primarily in the liver. The clearance is mediated predominantly by the cytochrome P450 (CYP) microsomal isoenzymes. The major metabolic pathway is catalyzed by CYP3A4, with a minor contribution from CYP2C9.[1]
• Active Metabolite: The principal metabolic transformation is N-demethylation of the piperazine ring, which produces the major circulating metabolite, N-desmethylsildenafil.[1] This metabolite is not inert; it also possesses inhibitory activity against PDE5. Its in-vitro potency is approximately 50% that of the parent sildenafil molecule, and it has a similar selectivity profile for other phosphodiesterases.[1] Plasma concentrations of this metabolite are about 40% of those of sildenafil, and it is estimated to contribute approximately 20% of the total pharmacological effect following a dose.[1]

The central role of CYP3A4 in sildenafil's metabolism is the primary driver of its most clinically significant drug-drug interactions. Co-administration with potent inhibitors of CYP3A4, such as the protease inhibitor ritonavir or the antifungal ketoconazole, can dramatically slow down sildenafil's metabolism.[4] This leads to reduced clearance and a substantial increase in the plasma concentration and AUC of sildenafil. For example, co-administration with ritonavir has been shown to cause an 11-fold increase in sildenafil AUC.[4] Such elevated drug levels significantly increase the risk and severity of dose-dependent adverse effects like hypotension. This mechanistic understanding is the reason why significant dose reductions (e.g., starting at 25 mg for ED) are mandated when sildenafil is used with strong CYP3A4 inhibitors.[4] Conversely, co-administration with strong CYP3A4 inducers, such as the antibiotic rifampin or the herbal supplement St. John's Wort, can accelerate sildenafil's metabolism, leading to lower plasma concentrations and a potential loss of therapeutic efficacy.[4]

Excretion

• Route of Elimination: Following metabolism, sildenafil is eliminated from the body primarily as metabolites. The main route of excretion is via the feces, which accounts for approximately 80% of an administered oral dose. A smaller fraction, about 13% of the dose, is excreted in the urine.[1] This indicates that biliary excretion is the predominant clearance pathway.
• Half-Life: The terminal elimination half-life (t1/2​) of sildenafil and its active N-desmethyl metabolite is approximately 3 to 5 hours.[1] This relatively short half-life is consistent with the observed duration of clinical effect, which is typically around 4 hours, although the response may diminish after 2 hours.[1]
• Clearance: The total body clearance of sildenafil is documented to be 41 L/h.[1]

The pharmacokinetic profile is also altered in specific populations, which necessitates clinical dose adjustments. For instance, reduced clearance of sildenafil has been observed in healthy elderly volunteers (age >65), leading to plasma concentrations approximately 90% higher than those in younger volunteers.[1] Similarly, patients with severe renal impairment (creatinine clearance < 30 mL/min) or hepatic impairment (e.g., cirrhosis) also exhibit higher plasma levels due to decreased clearance.[4] This direct relationship between altered physiology, altered pharmacokinetics, and increased drug exposure is the basis for the clinical recommendation of a lower starting dose (e.g., 25 mg for ED) in these populations to maintain a favorable risk-benefit balance.[4]

Clinical Applications and Efficacy

Sildenafil's well-characterized mechanism of action has been leveraged to treat two distinct medical conditions, with ongoing research exploring its potential in several other areas. Its clinical applications highlight the ubiquity of the PDE5/cGMP pathway in vascular pathophysiology across different organ systems. The drug's utility is not limited to a single disease but extends to any condition where modulating this fundamental signaling pathway can provide a therapeutic benefit.

Primary Indication: Erectile Dysfunction (ED)

• Status and Efficacy: Sildenafil, marketed as Viagra, was the first FDA-approved oral therapy for ED and remains a first-line, standard-of-care treatment.[1] Its efficacy is firmly established through numerous large-scale, randomized, placebo-controlled trials.[15] In the presence of sexual stimulation, it effectively restores impaired erectile function by enhancing blood flow to the penis.[1] Clinical studies have consistently demonstrated statistically significant improvements in the ability to achieve and maintain an erection sufficient for satisfactory sexual intercourse compared to placebo.[15] Its effectiveness has been proven across a broad spectrum of patient populations, including those with ED of organic, psychogenic, or mixed etiology, as well as in difficult-to-treat subgroups such as men with diabetes mellitus and those experiencing antidepressant-induced ED.[3]
• Clinical Trials and Formulations: The initial Phase II and III trials established the dose-response relationship and safety of sildenafil for ED.[31] Subsequent trials have compared its efficacy and psychological outcomes against other PDE5 inhibitors like tadalafil.[33] Research has also focused on developing alternative formulations to improve patient convenience or modify pharmacokinetic profiles, including orally dissolving films and sublingual wafers designed to be bioequivalent to the standard oral tablet.[8]

Primary Indication: Pulmonary Arterial Hypertension (PAH)

• Status and Efficacy: Sildenafil, marketed as Revatio, is approved by the FDA for the treatment of adults with WHO Group I PAH.[1] Its primary benefit is to improve exercise ability and delay clinical worsening of the disease.[1] The mechanism involves vasodilation of the pulmonary vascular bed, which reduces pulmonary arterial pressure and alleviates the strain on the right ventricle.[4] Efficacy was established in short-term studies (12 to 16 weeks) primarily in patients with NYHA Functional Class II-III symptoms. The benefit has been demonstrated in patients with idiopathic PAH and PAH associated with connective tissue disease.[1]
• Regulatory Nuances: While the core indication is consistent, specific labels vary slightly across regulatory bodies. The European Medicines Agency (EMA) also approves sildenafil for pediatric patients aged 1 to 17 years with PAH.[1] However, long-term, high-dose use in pediatric populations is cautioned against, as a clinical trial observed an increase in mortality with increasing doses in children with PAH, with deaths occurring after approximately one year of use.[4]

Off-Label and Investigational Uses

The vasodilatory and cell-signaling effects of sildenafil have prompted investigation into its use for other conditions:

• Raynaud's Phenomenon: Sildenafil is used off-label to treat severe secondary Raynaud's phenomenon, a condition characterized by vasospasm in the peripheral arteries of the fingers and toes. It has shown moderate efficacy in reducing the frequency and duration of vasospastic episodes and helping to heal ischemic digital ulcers.[3] This application is a logical extension of its vasodilatory mechanism to another vascular bed.
• Altitude Sickness: The drug has been studied for its potential to prevent high-altitude pulmonary edema (HAPE) and improve exercise performance at high altitudes by mitigating hypoxia-induced pulmonary vasoconstriction. However, the evidence for its efficacy is mixed, and it is not currently recommended as a standard treatment for this indication.[3]
• Female Sexual Arousal Disorder: Despite interest in its potential effects on female genital blood flow, there is currently no clear or convincing evidence to support the effectiveness of sildenafil for treating female sexual dysfunction.[3]
• Post-Prostatectomy ED Prevention: A Phase 3 clinical trial has investigated the use of sildenafil to preserve erectile function in men undergoing radiotherapy and hormone therapy for prostate cancer, a common cause of treatment-induced ED.[32]

Preclinical and Veterinary Research

• Canine Megaesophagus: In veterinary medicine, a randomized controlled trial demonstrated that sildenafil significantly reduced regurgitation episodes and promoted weight gain in dogs with congenital idiopathic megaesophagus (CIM). The proposed mechanism is the relaxation of the lower esophageal sphincter, facilitating the passage of food into the stomach.[19]
• Ischemia-Reperfusion Injury: Preclinical studies in various animal models (porcine, rodent) have suggested that sildenafil may have a cardioprotective and neuroprotective role against ischemia-reperfusion injury, potentially by modulating the renin-angiotensin system and improving blood flow to compromised tissues.[11]
• Oncology: In-vitro research has explored the potential anti-cancer properties of sildenafil. Because PDE5 is overexpressed in some tumor types, its inhibition has been shown to decrease cell viability, invasion, and migration in oral squamous cell carcinoma cell lines, suggesting a potential role in modulating the tumor microenvironment or cell signaling.[19]

Dosing, Administration, and Therapeutic Regimens

The administration of sildenafil is tailored to its specific indication, the patient population, and factors that may alter its pharmacokinetic profile, such as age, organ function, and concomitant medications. A variety of formulations are available to meet these diverse clinical needs.

Available Formulations

• Oral Tablets: This is the most common formulation. For the treatment of ED, sildenafil is available as film-coated tablets in strengths of 25 mg, 50 mg, and 100 mg.[4] For PAH, it is available as a 20 mg tablet.[4]
• Oral Suspension: A powder for reconstitution into a 10 mg/mL oral suspension is available (e.g., under the brand names Revatio and Liqrev).[4] This formulation is primarily used for the treatment of PAH in pediatric patients or in adults who have difficulty swallowing tablets.[4]
• Intravenous (IV) Injection: An injectable formulation (10 mg/12.5 mL, equivalent to 0.8 mg/mL) is available for the continued treatment of PAH in hospitalized patients who are temporarily unable to take oral medication. This ensures continuity of therapy.[3]
• Other Formulations: To offer alternatives to standard tablets, other oral formulations have been developed, including chewable tablets and orally disintegrating films or wafers, which dissolve in the mouth without the need for water.[1]

Dosing Regimens

The recommended dosing for sildenafil is highly dependent on the indication, as summarized in Table 2.

Table 2: Summary of Dosing Regimens for Sildenafil

Indication	Patient Population	Formulation	Recommended Dose	Frequency	Key Considerations
Erectile Dysfunction	Adults <65 years	Oral Tablet	50 mg (starting dose)	As needed, ~1 hour before sexual activity (max once daily)	Dose may be titrated to 25 mg or 100 mg based on efficacy and tolerability. Onset may be delayed by a high-fat meal.1
Erectile Dysfunction	Adults ≥65 years; Severe Renal/Hepatic Impairment; Concomitant CYP3A4 inhibitors	Oral Tablet	25 mg (starting dose)	As needed, ~1 hour before sexual activity (max once daily)	Lower starting dose is recommended due to reduced drug clearance and increased plasma concentrations in these populations.4
Pulmonary Arterial Hypertension	Adults	Oral Tablet/Suspension	20 mg	Three times a day (4-6 hours apart)	Dose may be titrated up to 80 mg TID in some cases, though this is less common. Continue therapy even if feeling well.4
Pulmonary Arterial Hypertension	Adults (unable to take oral)	IV Injection	10 mg	Three times a day (as IV bolus)	Intended for temporary substitution of oral therapy to ensure no interruption in treatment.4
Pulmonary Arterial Hypertension	Pediatrics (≥1 year)	Oral Suspension	Weight-based: 10 mg (for ≤20 kg) or 20 mg (for >20 kg)	Three times a day	Dose may be adjusted, but max dose is typically 40 mg TID. Chronic high-dose use is cautioned against due to safety signals.4

Safety, Tolerability, and Risk Management

Sildenafil has a well-established safety profile and is generally well-tolerated when used as directed. However, its potent vasodilatory mechanism is also the source of its most significant adverse effects and contraindications. A thorough understanding of this profile is essential for safe prescribing and patient counseling. The entire safety profile can be understood as a logical consequence of its primary pharmacological action—PDE5-mediated vasodilation—which occurs not only in the target tissues but to varying degrees throughout the body.

Contraindications

Certain conditions and concomitant medications absolutely preclude the use of sildenafil due to the risk of life-threatening adverse events.

• Concomitant Use of Nitrates: This is the most critical and absolute contraindication. Sildenafil must not be used in patients taking any form of organic nitrates or nitric oxide donors. This includes prescription anti-anginal medications such as nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate, as well as the recreational drugs known as "poppers" (e.g., amyl nitrite).[3] The interaction is pharmacodynamic and synergistic: nitrates increase the production of cGMP, while sildenafil blocks its degradation. The resulting massive accumulation of cGMP leads to profound vasodilation and a severe, precipitous, and potentially fatal drop in blood pressure.[4]
• Concomitant Use of Guanylate Cyclase Stimulators: Use with drugs like riociguat, which also increase cGMP levels by directly stimulating guanylate cyclase, is contraindicated for the same reason of synergistic hypotension.[3]
• Hypersensitivity: Known hypersensitivity to sildenafil or any component of the formulation is a contraindication.[3]

Common Adverse Drug Reactions (ADRs)

The most frequently reported side effects are generally mild, transient, and directly related to the systemic vasodilatory effects of sildenafil.[1]

• Vasodilatory Effects: Headache (from cranial vasodilation), facial flushing (from cutaneous vasodilation), and nasal congestion (from vasodilation of the nasal mucosa) are very common.[8]
• Gastrointestinal Effects: Dyspepsia (indigestion or heartburn) and nausea are also frequently reported.[4]
• Musculoskeletal Effects: Back pain and myalgia (muscle pain) can occur.[4]
• Visual Disturbances: As a result of off-target inhibition of PDE6 in the retina, patients may experience transient visual side effects. These include blurred vision, increased sensitivity to light, and changes in color vision, most notably cyanopsia (a blue tinge to vision or difficulty distinguishing between blue and green).[4]

Serious and Rare Adverse Events

Although less common, several serious adverse events have been reported in association with sildenafil use and require immediate medical attention.

• Priapism: A prolonged and painful erection lasting more than 4 hours is a rare but serious adverse event. It is a medical emergency that can lead to permanent damage to the penile tissue if not treated promptly.[4] Patients with anatomical deformation of the penis or conditions that predispose to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) should use sildenafil with caution.[4]
• Sudden Vision Loss (NAION): Rare cases of non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden, often permanent vision loss in one eye, have been reported in temporal association with PDE5 inhibitor use. NAION is thought to be caused by ischemia (insufficient blood flow) to the optic nerve. While a direct causal link has not been definitively established, caution is advised when prescribing sildenafil to patients with a history of NAION or with a "crowded" optic disk, which is an anatomical risk factor.[4]
• Sudden Hearing Loss: Rare postmarketing reports describe a sudden decrease or loss of hearing, which may be accompanied by tinnitus (ringing in the ears) and dizziness. A causal relationship has not been proven, but patients experiencing these symptoms should seek prompt medical care.[4]
• Cardiovascular Events: Serious cardiovascular events, including myocardial infarction, stroke, arrhythmia, and sudden cardiac death, have been reported in men taking sildenafil. However, most of these men had pre-existing cardiovascular disease or other risk factors. It remains unclear whether these events were caused directly by sildenafil, by the physiological strain of sexual activity, by the underlying disease, or by a combination of these factors.[9]

Drug and Food Interactions

Managing potential interactions is a key component of sildenafil risk management. A summary of the most significant interactions is provided in Table 3.

Table 3: Clinically Significant Drug Interactions with Sildenafil

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Recommended Management
Organic Nitrates (e.g., nitroglycerin, "poppers")	Synergistic increase in cGMP levels (nitrates increase production, sildenafil blocks degradation)	Severe, potentially fatal hypotension	Absolute Contraindication. Concomitant use is forbidden.3
Alpha-Adrenergic Blockers (e.g., doxazosin, tamsulosin)	Additive vasodilatory effects	Symptomatic hypotension, dizziness, syncope	Initiate sildenafil at the lowest dose (25 mg for ED). Administer drugs several hours apart. Use with caution.4
Strong CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole, itraconazole)	Inhibition of sildenafil metabolism	Markedly increased plasma concentrations of sildenafil, increasing risk of adverse effects	Dose reduction is required. For ED, start with 25 mg and do not exceed 25 mg in 48 hours for ritonavir.4
Moderate CYP3A4 Inhibitors (e.g., erythromycin, cimetidine)	Inhibition of sildenafil metabolism	Increased plasma concentrations of sildenafil	Use with caution. Consider starting at the lowest dose (25 mg for ED).1
CYP3A4 Inducers (e.g., rifampin, bosentan, St. John's Wort)	Acceleration of sildenafil metabolism	Decreased plasma concentrations of sildenafil, potentially leading to loss of efficacy	Avoid concomitant use where possible, or anticipate the need for dose adjustments of sildenafil.4
Guanylate Cyclase Stimulators (e.g., riociguat)	Synergistic increase in cGMP levels (riociguat increases production, sildenafil blocks degradation)	Severe hypotension	Contraindicated. Concomitant use is forbidden.3

• Food Interactions:
• Grapefruit Juice: As a known inhibitor of intestinal CYP3A4, grapefruit juice can increase sildenafil plasma levels. Patients taking sildenafil for PAH are specifically advised to avoid it.[8]
• High-Fat Meals: As previously noted, high-fat meals can delay the absorption and onset of action of sildenafil, though they do not significantly impact the total amount absorbed.[1]
• Alcohol: While moderate alcohol consumption is generally permissible, excessive intake can independently impair erectile function, potentially counteracting the drug's benefit. It may also increase the likelihood of side effects like headache and dizziness.[29]

Commercial Landscape and Regulatory Status

The commercial journey of sildenafil is as remarkable as its scientific discovery, serving as a textbook case study in the lifecycle of a blockbuster pharmaceutical product. Its history encompasses brand creation, market dominance, patent litigation, and the eventual transition to a highly competitive generic market.

Brand Names and Formulations

• Originator Brands: Pfizer established sildenafil in the global market under two iconic brand names, each tied to a specific indication: Viagra for erectile dysfunction and Revatio for pulmonary arterial hypertension.[1] A newer branded oral suspension for PAH, Liqrev, has also been introduced.[9]
• Global and Over-the-Counter Brands: In some countries, such as the UK, sildenafil for ED is available as a non-prescription, over-the-counter medication from pharmacies under various brand names, including Aronix, Liberize, and Nipatra.[1] A multitude of other international brand names exist, such as Grandipam, Vizarsin, and Mysildecard, reflecting its widespread global use.[1]

Generic Sildenafil

The expiration of Pfizer's patents triggered the "patent cliff," a phenomenon where originator drug revenues decline sharply due to the entry of lower-cost generic competitors.

• Market Entry: Following patent expiries, which occurred at different times in different countries, a large number of pharmaceutical companies began manufacturing and marketing generic sildenafil. Major generic manufacturers include Teva, Mylan (now Viatris), Sandoz, Accord Healthcare, Aurobindo Pharma, and Dr. Reddy's Laboratories, among many others.[3]
• Impact on Price and Access: The introduction of generic competition led to a dramatic reduction in the price of sildenafil, significantly increasing its accessibility to patients.[26]
• Therapeutic Equivalence and Patient Perception: All approved generic versions are required to be therapeutically equivalent to the brand-name product, containing the same active ingredient in the same dosage and meeting the same standards of quality and performance. However, generic tablets often differ in cosmetic characteristics such as color, shape, and size.[26] For example, Viagra is famously a blue, diamond-shaped pill, whereas generic versions may be white and round or blue and oval. While these differences do not affect the drug's action, they can occasionally influence patient perception and brand loyalty.[26] A selection of international brands and manufacturers is detailed in Table 4.

Table 4: Selected International Brand Names and Manufacturers of Sildenafil

Brand Name	Indication(s)	Manufacturer/Marketer	Region(s) of Availability
Viagra	Erectile Dysfunction	Pfizer / Viatris	Global
Revatio	Pulmonary Arterial Hypertension	Pfizer / Viatris	Global
Liqrev	Pulmonary Arterial Hypertension	Libervant	US
Aronix	Erectile Dysfunction	Various (OTC)	UK
Vizarsin	Erectile Dysfunction, PAH	Consilient Health / KRKA	EU
Teva Sildenafil	Erectile Dysfunction, PAH	Teva Pharmaceuticals	Global
Sandoz Sildenafil	Erectile Dysfunction	Sandoz (Novartis)	Global
Accord Sildenafil	Erectile Dysfunction	Accord Healthcare	Global
Mylan Sildenafil	Erectile Dysfunction	Mylan / Viatris	Global

Patent History and Litigation

The commercial success of sildenafil was protected for years by a robust patent portfolio, but this protection was challenged as it neared expiration.

• US Patents: In the United States, Pfizer held two key patents: one covering the sildenafil substance and its use for cardiovascular disease (marketed as Revatio), which expired in 2012, and a second "use patent" covering its application for erectile dysfunction (marketed as Viagra), which was set to expire in 2020.[3]
• Patent Litigation: In the lead-up to these expirations, Pfizer engaged in litigation to defend its market exclusivity. A notable case involved a lawsuit by Teva Pharmaceuticals to invalidate the ED use patent. While Pfizer initially prevailed in a 2011 court case, the companies later reached a settlement agreement that allowed Teva to launch a generic version of Viagra in the US in December 2017, several years before the final patent expired.[3]
• International Patent Expiry: The patent expiry timeline varied significantly by country. In Brazil, the patent expired in 2010.[3] In Canada, a landmark legal decision occurred in 2012 when the Supreme Court of Canada invalidated Pfizer's Viagra patent outright. The court ruled that Pfizer had failed to provide sufficient disclosure in its original patent application, a practice the court described as "gaming the system." This decision allowed Teva Canada to launch a generic version immediately, forcing Pfizer to drastically reduce the price of Viagra in Canada to remain competitive.[3]

This complete commercial arc—from a highly profitable, patent-protected monopoly to a fragmented, competitive generic market—positions sildenafil as a quintessential case study in the economic lifecycle of a modern blockbuster drug. It illustrates the immense value generated during the period of market exclusivity, the strategic importance of patent defense, and the transformative impact of the patent cliff on pricing and market dynamics.

Synthesis and Concluding Remarks

Sildenafil stands as one of the most significant and transformative pharmaceutical innovations of the late 20th century. Its impact extends far beyond its direct clinical applications, having reshaped medical practice, public health discourse, and the pharmaceutical industry itself. A comprehensive analysis reveals a molecule whose history and properties offer profound lessons in pharmacology, clinical medicine, and drug development.

The drug's well-established risk-benefit profile is favorable for its approved indications when used under appropriate medical supervision. Its safety is predictable and manageable, with the vast majority of adverse effects and contraindications stemming directly from its primary vasodilatory mechanism. The absolute contraindication with nitrate medications, while critical, is a well-understood and avoidable interaction rooted in fundamental pharmacology.

Perhaps sildenafil's greatest legacy lies in its societal impact. Prior to 1998, erectile dysfunction was a topic shrouded in stigma, often dismissed as a psychological failing or an inevitable consequence of aging. The arrival of Viagra, a simple and effective oral pill, medicalized and legitimized the condition.[10] It sparked a global conversation about male sexual health, encouraging millions to seek medical treatment and fostering a greater understanding of the physiological underpinnings of sexual function.[17]

From a scientific perspective, sildenafil is a paradigm of modern pharmacology. Its story is a testament to the power of serendipity, where an unexpected observation in a failed clinical trial for angina led to a world-changing therapy for ED. It is also a model of rational drug design, with its molecular structure meticulously engineered to mimic the natural substrate of its target enzyme, PDE5. Finally, its journey from an angina drug to an ED treatment and then to a therapy for PAH showcases the immense potential of mechanism-based drug repurposing, demonstrating how a single pharmacological principle can be applied to multiple distinct pathologies.

The field of PDE5 inhibition continues to evolve, with the development of other agents like tadalafil and vardenafil offering different pharmacokinetic profiles and clinical characteristics, providing more tailored options for patients.[29] Ongoing research continues to explore the potential of sildenafil in other areas, including neuroprotection and oncology, suggesting its story may not yet be complete.

In conclusion, sildenafil is more than just a successful drug. It is a scientific and cultural landmark that not only provided a solution for millions of patients but also fundamentally altered our approach to and conversation about sexual health. Its journey from a laboratory curiosity to a global phenomenon encapsulates the intricate interplay of rational science, serendipitous discovery, clinical validation, and commercial strategy that defines modern pharmaceutical innovation.

Works cited

1. Sildenafil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/drugs/DB00203
2. Sildenafil | C22H30N6O4S | CID 135398744 - PubChem, accessed July 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Sildenafil
3. Sildenafil - Wikipedia, accessed July 14, 2025, https://en.wikipedia.org/wiki/Sildenafil
4. Sildenafil - StatPearls - NCBI Bookshelf, accessed July 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK558978/
5. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond - PMC, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7097805/
6. Viagra's Journey to Blockbuster Patent and the Single Journal Article It Cites - ACS Axial, accessed July 14, 2025, https://axial.acs.org/medicinal-chemistry/viagra-s-journey-to-blockbuster-patent-and-the-single-journal-article-it-cites
7. Viagra's famously surprising origin story is actually a pretty common way to find new drugs, accessed July 14, 2025, https://qz.com/1070732/viagras-famously-surprising-origin-story-is-actually-a-pretty-common-way-to-find-new-drugs
8. About sildenafil (Viagra) - NHS, accessed July 14, 2025, https://www.nhs.uk/medicines/sildenafil-viagra/about-sildenafil-viagra/
9. Sildenafil: MedlinePlus Drug Information, accessed July 14, 2025, https://medlineplus.gov/druginfo/meds/a699015.html
10. The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction, accessed July 14, 2025, https://pure.johnshopkins.edu/en/publications/the-serendipitous-story-of-sildenafil-an-unexpected-oral-therapy-
11. The discovery and development of of Viagra® (sildenafil citrate) - ResearchGate, accessed July 14, 2025, https://www.researchgate.net/publication/251403464_The_discovery_and_development_of_of_ViagraR_sildenafil_citrate
12. A Short History of Erectile Dysfunction and Viagra - Searcy Law, accessed July 14, 2025, https://www.searcylaw.com/short-history-erectile-dysfunction-viagra/
13. The True Story of 'Men Up' & the World's First Viagra Drug Trials - Esquire, accessed July 14, 2025, https://www.esquire.com/uk/culture/a46025063/men-up-the-true-story/
14. How Viagra Was Discovered By Accident | Viagra: The Little Blue Pill That Changed The World - YouTube, accessed July 14, 2025, https://www.youtube.com/watch?v=0KFOeaDFstM
15. FDA Approves Impotence Pill, Viagra - ScienceDaily, accessed July 14, 2025, https://www.sciencedaily.com/releases/1998/04/980401074901.htm
16. FDA approves Viagra | March 27, 1998 - History.com, accessed July 14, 2025, https://www.history.com/this-day-in-history/march-27/fda-approves-viagra
17. Viagra's 20th Anniversary: What People Said About Blue Pill - Time Magazine, accessed July 14, 2025, https://time.com/5212572/viagra-20th-anniversary/
18. Revatio (sildenafil citrate) FDA Approval History - Drugs.com, accessed July 14, 2025, https://www.drugs.com/history/revatio.html
19. Sildenafil free base | CAS - MedKoo Biosciences, accessed July 14, 2025, https://www.medkoo.com/products/28821
20. Sildenafil | CAS 139755-83-2 | Cayman Chemical | Biomol.com, accessed July 14, 2025, https://www.biomol.com/products/chemicals/biochemicals/sildenafil-cay10008671-10
21. Sildenafil (CRM) (CAS Number: 139755-83-2) | Cayman Chemical, accessed July 14, 2025, https://www.caymanchem.com/product/41132/sildenafil-(crm)
22. SILDENAFIL - gsrs, accessed July 14, 2025, https://gsrs.ncats.nih.gov/ginas/app/beta/substances/3M7OB98Y7H
23. Sildenafil - brand name list from Drugs.com, accessed July 14, 2025, https://www.drugs.com/ingredient/sildenafil.html
24. The structure of sildenafil, accessed July 14, 2025, https://www.ch.ic.ac.uk/local/projects/p_hazel/structure2.html
25. Sildenafil (CAS Number: 139755-83-2) - Cayman Chemical, accessed July 14, 2025, https://www.caymanchem.com/product/10008671/sildenafil
26. Brands of sildenafil - Dr Fox, accessed July 14, 2025, https://www.doctorfox.co.uk/news/brands-of-sildenafil/
27. 3D structure for Sildenafil (DB00203) | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB00203
28. Sildenafil (oral route) - Mayo Clinic, accessed July 14, 2025, https://www.mayoclinic.org/drugs-supplements/sildenafil-oral-route/description/drg-20066989
29. Common questions about sildenafil - NHS, accessed July 14, 2025, https://www.nhs.uk/medicines/sildenafil-viagra/common-questions-about-sildenafil/
30. Sildenafil: Viagra for Erectile Dysfunction - Cleveland Clinic, accessed July 14, 2025, https://my.clevelandclinic.org/health/drugs/20690-sildenafil-tablets-erectile-dysfunction
31. Impotence Completed Phase 2 Trials for Sildenafil (DB00203) | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/indications/DBCOND0030686/clinical_trials/DB00203?phase=2&status=completed
32. Sildenafil Completed Phase 3 Trials for Erectile Dysfunction / Prostate Cancer Prevention, accessed July 14, 2025, https://go.drugbank.com/drugs/DB00203/clinical_trials?conditions=DBCOND0029956%2CDBCOND0062462&phase=3&purpose=prevention&status=completed
33. Sildenafil Completed Phase 3 Trials for Erectile Dysfunction Treatment | DrugBank Online, accessed July 14, 2025, https://go.drugbank.com/drugs/DB00203/clinical_trials?conditions=DBCOND0029956&phase=3&purpose=treatment&status=completed
34. Sildenafil: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 14, 2025, https://www.rxlist.com/sildenafil/generic-drug.htm
35. Everything You Need to Know About Generic Viagra - GoodRx, accessed July 14, 2025, https://www.goodrx.com/sildenafil/generic-viagra-what-you-should-know
36. FDA Approves Intravenous Formulation Of Pfizer's Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension, accessed July 14, 2025, https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_intravenous_formulation_of_pfizer_s_revatio_sildenafil_for_the_treatment_of_pulmonary_arterial_hypertension
37. www.nhs.uk, accessed July 14, 2025, https://www.nhs.uk/medicines/sildenafil-viagra/about-sildenafil-viagra/#:~:text=If%20you%20buy%20sildenafil%20for,brand%20names%20Revatio%20and%20Grandipam.
38. Generic Viagra Availability - Drugs.com, accessed July 14, 2025, https://www.drugs.com/availability/generic-viagra.html
39. The rise and fall of Viagra: Viagra has probably received more media hype than any other drug. Abi Berger examines how this massive publicity will affect general practitioners, who may eventually have to prescribe the impotence treatment - PMC, accessed July 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1113924/